Everything You Need to Know About the Drug Development Process

February 13, 2020

New medications entering the market can impact both your organization’s pharmacy spend and your members’ cost share.

With thousands of drugs in development, it’s important to stay ahead of the curve and to pay attention to the select few that are likely to get FDA approval, hit the market and make a splash.

Luckily, our team of pharmacists and other experts has you covered. In this blog series, we’ll explore some of the most important drugs launching this year or nearing the end of their development cycle and present how these may impact you and your members. But before we do that, let’s take a quick look at what it takes to develop a new drug.

DRUG DEVELOPMENT: HOW IT WORKS

In order to know when a new medication is coming to market, it is important to understand the process for developing a new drug. Bringing a new drug to market is a lengthy and complex process that takes an average of 10 years, including 6-7 years of clinical trials.1 The average cost for developing a new drug is $2.6 billion and only about 12% of drugs that enter clinical trials will ultimately be approved for sale.1 In the United States, the Food and Drug Administration provides regulatory oversight and undertakes the final review of each new drug.

The Drug Development Process

Source: FDA.gov. Learn About Drug and Device Approvals.

Here is a quick summary of what happens at each stage:

Discovery & DevelopmentNarrows down thousands of potential drugs
Pre-Clinical ResearchDetermines if the drug is safe to test on people
Clinical Research/Trials
Phase ITests safety
Fewer than 100 volunteers, usually healthy, participate
Length: Several months
~70% of drugs move to Phase II
Phase IIAssesses safety and efficacy
Several hundred volunteers with a condition participate
Length: Months to 2 years
~33% of drugs move to Phase III
Phase IIIDemonstrates safety and efficacy
300-3000 volunteers with a condition participate
Length: 1 to 4 years
25-30% drugs move to FDA Review
FDA ReviewFDA reviews the application and decides whether to approve the drug for sale; this process usually takes 10 months, although drugs flagged for priority review may be approved in 6 months
FDA Post-Market Safety MonitoringOngoing reporting and data collection after the drug comes to market

For this series, we will focus on recently approved drugs that are undergoing FDA review or that are approaching the end of Phase III clinical trials. In some instances, we will also highlight promising drugs that are in Phase II trials or just beginning Phase III trials. While these won’t be coming to market in 2020, they have the potential to make a real impact in coming years.

Join us next week for a detailed overview of the most important specialty medications of 2020.

Biopharmaceutical Research & Development: The Process Behind New Medicines. Pharmaceutical Research and Manufacturers of America. http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf. Published May 2015. Accessed January 8, 2020.

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Examining Trends that Drive Informed Decisions

Now Available: 8th Annual Drug Trend Report

See the latest results and access industry insights you need to navigate current trend drivers.

Related blogs

Navigating Healthcare and Improving Outcomes

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…

PBM 101: Why the Model Matters

PBM 101: Why the Model Matters

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…

Associate Resource Group Spotlight: Green Team

Associate Resource Group Spotlight: Green Team

The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….

PBM 101: The Three PBM Business Models

PBM 101: The Three PBM Business Models

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….

Achieving Outstanding Results with Tailored Network Strategies

Achieving Outstanding Results with Tailored Network Strategies

A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…

Breaking Through Barriers with Value-Based Plan Design

Breaking Through Barriers with Value-Based Plan Design

Facing increased pharmacy benefit expenses, Blain’s Farm and Fleet, a Midwestern employer group, desired to improve plan performance. Specifically it was interested in educating eligible members about the benefits available to them, promoting cost-effective…

Finding a Solution to Lower Prescription Drug Costs

Finding a Solution to Lower Prescription Drug Costs

The Rural Arizona Group Health Trust (RAGHT) wanted to gain better control of its escalating drug trend with its large, traditional pharmacy benefit manager (PBM). Having only worked with traditional PBMs in the past, RAGHT was interested in exploring…

previous arrow
next arrow